GlaxoSmithKline (GSK) and Genmab A/S (GEN.CO) Release: New Drug Application for Arzerra Submitted in Japan  
4/27/2012 9:28:53 AM

COPENHAGEN, Denmark, April 27, 2012 (GLOBE NEWSWIRE) -- GlaxoSmithKline (GSK) and Genmab A/S (Copenhagen:GEN) announced today the submission of a New Drug Application (NDA) to the Japanese Ministry of Health, Labor and Welfare (MHLW) for Arzerra(R) (ofatumumab) for the treatment of chronic lymphocytic leukemia (CLL).